Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01675960 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children
A Phase 2 study, sponsored by Gillette Children's Specialty Healthcare.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01675960: Clinical Trial Phase 2 study, sponsored by Gillette Children's Specialty Healthcare.
NCT01675960 is a Phase 2 study that was terminated before completion, run by Gillette Children's Specialty Healthcare. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01675960, a Phase 2 study, was terminated before completion, sponsored by Gillette Children's Specialty Healthcare.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study is a prospective, randomized, double blind, placebo controlled, crossover clinical trial looking at whether gabapentin can provide symptom relief for chronic irritability in neurologically impaired children. The investigators hypothesize gabapentin ins beneficial and safe for children with chronic irritability that persists despite identification and appropriate management of symptom sources.
Primary Outcome
We will determine whether gabapentin provides symptom relief for chronic irritability in neurologically impaired children, who continue to have irritability even though potential sources may have been identified and treated, or have sources that have not been identified.
Interventions
- DRUG placebo
- DRUG Gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-04 |
| Est. Completion | 2017-07 |
| Phase | Phase 2 |
Why NCT01675960 stopped before completion
NCT01675960 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01675960 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01675960 about?
NCT01675960 is a clinical study titled "Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children". This study is a prospective, randomized, double blind, placebo controlled, crossover clinical trial looking at whether gabapentin can provide symptom relief for chronic irritability in neurologically impaired children. The investigators hypothesize gabapentin ins beneficial and safe for children wit...
What is the current status of trial NCT01675960?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-04. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01675960?
The interventions under investigation include: placebo (DRUG), Gabapentin (DRUG).
Who is sponsoring clinical trial NCT01675960?
This trial is sponsored by Gillette Children's Specialty Healthcare, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01675960's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia